• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Alliance Imaging posts loss in 1994

Article

Mobile MRI chain Alliance Imaging posted a $19 million loss as part of its 1994 annual results,based largely on a non-recurring $13.8 million charge in the fourthquarter. The charge was related to a write-down of assets andrepresents the completion of

Mobile MRI chain Alliance Imaging posted a $19 million loss as part of its 1994 annual results,based largely on a non-recurring $13.8 million charge in the fourthquarter. The charge was related to a write-down of assets andrepresents the completion of Alliance's restructuring plan, accordingto president and CEO Richard Zehner.

For the year, Alliance, of Orange, CA, had revenues of $57.9million, down 4.7% from the $60.7 million posted in 1993. Fourthquarter revenues rose 3.5%, however, to $14.9 million from $14.4million in the fourth quarter of 1993. The $19 million net losscompares to a $14.7 million net loss for the same period the yearbefore. Alliance completed a restructuring of its debt load latelast year (SCAN 12/28/94).

Recent Videos
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.